Objectives: This study sought to evaluate the long-term cost effectiveness of a clopidogrel
loading strategy before percutaneous coronary intervention (PCI) followed by continued …

ContextFollowing percutaneous coronary intervention (PCI), short-term clopidogrel therapy
in addition to aspirin leads to greater protection from thrombotic complications than aspirin …

Objectives: This study sought to determine the optimal timing of a 300-mg clopidogrel
loading dose before percutaneous coronary intervention (PCI) in patients enrolled in the …

Objectives: This study examined the incremental cost-effectiveness of extending clopidogrel
therapy from one month to one year after percutaneous coronary intervention (PCI) in an …

BACKGROUND: An increase in clopidogrel dose results in an improved inhibition of platelet
aggregation. However, whether an increase in clopidogrel dose may improve patient …

The optimal duration of clopidogrel administration after percutaneous coronary intervention
(PCI) remains unknown. Clopidogrel is currently recommended for minimums of 1 and 12 …

Background Drug-reimbursement policies may have an adverse effect on patient outcomes
if they interfere with timely access to efficacious medications for acute medical conditions …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with
clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the …

Background Clopidogrel was superior to aspirin monotherapy in secondary prevention after
percutaneous coronary intervention (PCI). Objectives The purpose of this study was to …